Business
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell
About this update from Fortress Biotech, Inc.
[{"type":"text","content":"Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2025. Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “We are pleased to report solid results for the second quarter of 2025, with total revenue of $15 million and a net sales contribution from Emrosi™ of $2.8 million during the period. The second quarter marks the first full quarter since Emrosi entered the market, and in a short period of time, we have delivered a strong initial prescription ramp for the product while payer coverage continues to expand. This momentum reflects growing physician and payer adoption, and confidence in Emrosi’s differentiated profile, including statistically superior efficacy versus Oracea® and placebo, as published in the Journal of the American Medical Association (JAMA) – Dermatology. With the Emrosi launch showing strong traction out of the gate, continued improvement in cash generation, and the execution of our focused dermatology commercial organization, we believe Journey Medical is well-positioned for continued growth and operating leverage in the second half of 2025 and beyond.” Financial Results: Total net product revenues were $15.0 million for the second quarter of 2025, compared to the prior year quarter of $14.9 million.The Company’s gross margin(1) increased to 67% in the second quarter of 2025, from 61% in the prior year quarter due to lower overall product cost of goods related to product sales mix and non-recurring charges in the prior year.Selling, general and administrative expenses were $11.9 million for the second quarter of 2025, a $1.6 million increase from the $10.3 million reported in the s...